Clinical review on triglycerides
U Laufs, KG Parhofer, HN Ginsberg… - European heart …, 2020 - academic.oup.com
Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies
have established that triglyceride-rich lipoproteins (TRL) and their remnants as important …
have established that triglyceride-rich lipoproteins (TRL) and their remnants as important …
A brief review of cardiovascular diseases, associated risk factors and current treatment regimes
Cardiovascular diseases (CVDs) are the leading cause of premature death and disability in
humans and their incidence is on the rise globally. Given their substantial contribution …
humans and their incidence is on the rise globally. Given their substantial contribution …
[HTML][HTML] Triglyceride lowering with pemafibrate to reduce cardiovascular risk
A Das Pradhan, RJ Glynn, JC Fruchart… - … England Journal of …, 2022 - Mass Medical Soc
Background High triglyceride levels are associated with increased cardiovascular risk, but
whether reductions in these levels would lower the incidence of cardiovascular events is …
whether reductions in these levels would lower the incidence of cardiovascular events is …
Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease
O Castañer, X Pintó, I Subirana, AJ Amor, E Ros… - Journal of the American …, 2020 - jacc.org
Background Genetic, observational, and clinical intervention studies indicate that circulating
levels of triglycerides and cholesterol transported in triglyceride-rich lipoproteins (remnant …
levels of triglycerides and cholesterol transported in triglyceride-rich lipoproteins (remnant …
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
N Bougarne, B Weyers, SJ Desmet, J Deckers… - Endocrine …, 2018 - academic.oup.com
Peroxisome proliferator–activated receptor α (PPAR α) is a nuclear receptor of clinical
interest as a drug target in various metabolic disorders. PPAR α also exhibits marked anti …
interest as a drug target in various metabolic disorders. PPAR α also exhibits marked anti …
Atualização da diretriz brasileira de dislipidemias e prevenção da aterosclerose–2017
AA Faludi, MCO Izar, JFK Saraiva… - Arquivos brasileiros de …, 2017 - SciELO Brasil
Material de distribuição exclusiva à classe médica. Os Arquivos Brasileiros de Cardiologia
não se responsabilizam pelo acesso indevido a seu conteúdo e que contrarie a …
não se responsabilizam pelo acesso indevido a seu conteúdo e que contrarie a …
The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk
PB Sandesara, SS Virani, S Fazio… - Endocrine …, 2019 - academic.oup.com
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death
worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of …
worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of …
[PDF][PDF] 2016 European Guidelines on cardiovascular disease prevention in clinical practice
MF Piepoli, AW Hoes, S Agewall… - Polish Heart …, 2016 - journals.viamedica.pl
2.3. 9. Wnioski................................................ 838 2.4. Inne markery ryzyka.......................................
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias
AL Catapano, I Graham, G De Backer… - Polish Heart …, 2016 - journals.viamedica.pl
5.1. Wpływ stylu życia na stężenie cholesterolu całkowitego i stężenie cholesterolu frakcji
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …